Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study

Rhea-AI Summary

Evoke Pharma reported promising results from a recent survey on GIMOTI, its newly launched treatment for diabetic gastroparesis. The survey, conducted in December 2020, involved 104 healthcare practitioners and indicated strong intent to prescribe GIMOTI, with 79% of targeted gastroenterologists and 89% of non-target gastroenterologists expressing positive prescribing trends. Notably, GIMOTI's unique nasal delivery method stands out as an alternative to oral treatments, addressing significant patient needs. The company's leadership expressed optimism over the results, paving the way for enhanced commercial efforts in 2021.

Positive

• 79% of target gastroenterologists indicated intent to prescribe GIMOTI.
• 89% of non-target gastroenterologists expressed intent to prescribe GIMOTI.
• GIMOTI is viewed as suitable for moderate to severe gastroparesis patients by 94% of target gastroenterologists.
• Nineteen healthcare practitioners reported already prescribing GIMOTI.
• Feedback from physicians highlights GIMOTI's effectiveness in patients who don’t respond to oral treatments.

Negative

• None.

Healthcare practitioner survey indicates physicians’ awareness and intent to prescribe newly-launched product

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced positive findings from the first market research for GIMOTI following its launch during the fourth quarter of 2020.

During December 2020, Evoke through its marketing partner, EVERSANA, conducted an ATU (Awareness, Trial, and Usage) Study, a quantitative survey to measure physician awareness, trial, and product usage, for GIMOTI. Approximately 104 total physician responses were captured. Survey respondents were split into three groups drawn from the healthcare practitioner (HCP) community; “target” gastroenterologists currently being called on by the field sales force (n = 61), other “non-target” gastroenterologists (n = 19), and primary care physicians (PCPs) who are not currently targeted for messaging (n = 24). Areas of interest that were queried included initial and future potential prescribing trends, and how HCPs viewed the suitability of GIMOTI in certain gastroparesis patient populations.

Key Findings:

• Indicated an intent to prescribe GIMOTI:
  • 79% of target gastroenterologists.
  • 89% of non-target gastroenterologists.
  • 50% of PCPs.
• Out of those target gastroenterologists indicating an intent to prescribe GIMOTI, 94% indicated GIMOTI would be “appropriate” to use in moderate to severe patients.
• A majority of each of the target and non-target gastroenterologists noted they intend to prescribe GIMOTI for both new and existing gastroparesis patients.
• Nineteen of all participating HCPs indicated that they have already written a prescription for GIMOTI.
  • HCPs indicated that the primary driver for prescribing GIMOTI was patients being switched to GIMOTI due to lack of efficacy of current treatments.

“While only a little over 10 weeks into our commercial launch, and occurring coincident with the pandemic environment and a holiday period, we are pleased with the ATU findings as they provide further direction for our commercial team and demonstrate that the GIMOTI message is hitting home, both with targeted and non-targeted healthcare care providers,” commented David Gonyer, R.Ph., Evoke Pharma President and CEO.

“Patients with diabetic gastroparesis often do not attain suitable relief from symptoms with oral treatments. This may be due to erratic absorption of orally administered drugs related to delayed gastric emptying or from vomiting up oral medications. Unfortunately, all traditional outpatient treatments used to manage symptoms of this disease are oral. GIMOTI is administered nasally, bypassing the GI system, with direct bloodstream delivery via the nasal membrane. This avoids the problem of unpredictable stomach emptying,” stated Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso. “I’ve been waiting for an alternative treatment like this for a long time. It is a major step forward in the treatment of gastroparesis and it will help many of my patients.”

“We are pleased with the ATU results and encouraged with recent feedback our 27 Gastroenterology Care Specialists are receiving from providers,” added Chris Quesenberry, Chief Commercial Officer. “The results of the market research follow the positive reception we are hearing from doctors who desire an alternative to existing oral therapies. They indicate that a nasal route of administration that bypasses the GI tract makes sense for this underserved patient population. In 2021, we will continue to build on the commercial launch of GIMOTI to increase awareness and ensure that patients and their providers have access to this important brand.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

About Gimoti™ (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Important Safety Information

WARNING: TARDIVE DYSKINESIA

• Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
• Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
• Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.
  

GIMOTI is not recommended for use in:

• Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
• { "@context": "https://schema.org", "@type": "FAQPage", "name": "Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study FAQs", "mainEntity": [ { "@type": "Question", "name": "What were the key findings from Evoke Pharma's survey regarding GIMOTI?", "acceptedAnswer": { "@type": "Answer", "text": "The survey revealed that 79% of targeted gastroenterologists and 89% of non-target gastroenterologists indicated intent to prescribe GIMOTI." } }, { "@type": "Question", "name": "How does GIMOTI compare to traditional treatments for diabetic gastroparesis?", "acceptedAnswer": { "@type": "Answer", "text": "GIMOTI offers a nasal spray delivery method, bypassing the gastrointestinal system, which is beneficial for patients who experience poor absorption with oral medications." } }, { "@type": "Question", "name": "When was GIMOTI launched?", "acceptedAnswer": { "@type": "Answer", "text": "GIMOTI was launched in the fourth quarter of 2020." } }, { "@type": "Question", "name": "How many healthcare practitioners participated in the survey conducted by Evoke Pharma?", "acceptedAnswer": { "@type": "Answer", "text": "The survey included 104 healthcare practitioners." } }, { "@type": "Question", "name": "What percentage of primary care physicians showed intent to prescribe GIMOTI?", "acceptedAnswer": { "@type": "Answer", "text": "50% of primary care physicians indicated an intent to prescribe GIMOTI." } } ] }

  FAQ

  What were the key findings from Evoke Pharma's survey regarding GIMOTI?

  The survey revealed that 79% of targeted gastroenterologists and 89% of non-target gastroenterologists indicated intent to prescribe GIMOTI.

  How does GIMOTI compare to traditional treatments for diabetic gastroparesis?

  GIMOTI offers a nasal spray delivery method, bypassing the gastrointestinal system, which is beneficial for patients who experience poor absorption with oral medications.

  When was GIMOTI launched?

  GIMOTI was launched in the fourth quarter of 2020.

  How many healthcare practitioners participated in the survey conducted by Evoke Pharma?

  The survey included 104 healthcare practitioners.

  What percentage of primary care physicians showed intent to prescribe GIMOTI?

  50% of primary care physicians indicated an intent to prescribe GIMOTI.